JANX logo

Janux Therapeutics (JANX)

Profile

Full Name

Janux Therapeutics, Inc.

Ticker Symbol

JANX

Exchange

NASDAQ

Country

United States

IPO

June 11, 2021

Indexes

Not included

Employees

81

Key Details

Price

$29.69(+3.49%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$10.59M(+30.99% YoY)

Annual EPS

-$1.28(+3.03% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 3, 25 HC Wainwright & Co.
Buy
Feb 28, 25 Scotiabank
Sector Perform
Dec 11, 24 Cantor Fitzgerald
Overweight
Dec 4, 24 Scotiabank
Sector Perform
Dec 3, 24 Stifel
Buy
Dec 3, 24 Leerink Partners
Outperform
Dec 3, 24 HC Wainwright & Co.
Buy
Nov 22, 24 Leerink Partners
Outperform
Nov 7, 24 HC Wainwright & Co.
Buy
Nov 7, 24 Cantor Fitzgerald
Overweight

Institutional Ownership

  • What is the ticker symbol for Janux Therapeutics?
  • Does Janux Therapeutics pay dividends?
  • What sector is Janux Therapeutics in?
  • What industry is Janux Therapeutics in?
  • What country is Janux Therapeutics based in?
  • When did Janux Therapeutics go public?
  • Is Janux Therapeutics in the S&P 500?
  • Is Janux Therapeutics in the NASDAQ 100?
  • Is Janux Therapeutics in the Dow Jones?
  • When was Janux Therapeutics's last earnings report?
  • When does Janux Therapeutics report earnings?
  • Should I buy Janux Therapeutics stock now?

What is the ticker symbol for Janux Therapeutics?

The ticker symbol for Janux Therapeutics is NASDAQ:JANX

Does Janux Therapeutics pay dividends?

No, Janux Therapeutics does not pay dividends

What sector is Janux Therapeutics in?

Janux Therapeutics is in the Healthcare sector

What industry is Janux Therapeutics in?

Janux Therapeutics is in the Biotechnology industry

What country is Janux Therapeutics based in?

Janux Therapeutics is headquartered in United States

When did Janux Therapeutics go public?

Janux Therapeutics's initial public offering (IPO) was on June 11, 2021

Is Janux Therapeutics in the S&P 500?

No, Janux Therapeutics is not included in the S&P 500 index

Is Janux Therapeutics in the NASDAQ 100?

No, Janux Therapeutics is not included in the NASDAQ 100 index

Is Janux Therapeutics in the Dow Jones?

No, Janux Therapeutics is not included in the Dow Jones index

When was Janux Therapeutics's last earnings report?

Janux Therapeutics's most recent earnings report was on Nov 6, 2024

When does Janux Therapeutics report earnings?

The next expected earnings date for Janux Therapeutics is May 8, 2025

Should I buy Janux Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page